Selective COX-2 inhibitors: A review of their structure-activity relationships

Iranian Journal of Pharmaceutical Research

Volumn 10, Issue 4, 2011, Pages 655-683

  Zarghi, Afshin ^a   Arfaei, Sara ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coxibs; Cyclooxygenase; NSAIDs; SAR; Selective COX 2 Inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE; CASPASE 3; CASPASE 9; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; CYTOCHROME C; DICLOFENAC; ETORICOXIB; GELATINASE A; GELATINASE B; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LUMIRACOXIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN 1; NAPROXEN; PROSTACYCLIN; PROSTAGLANDIN E2; PROTEIN BCL 2; PROTEIN KINASE C; ROFECOXIB; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR PEA3; VALDECOXIB;

ALZHEIMER DISEASE; ANGIOGENESIS; APOPTOSIS; ASTHMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOGENESIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FAMILIAL COLON POLYPOSIS; FIRST TRIMESTER PREGNANCY; HUMAN; IMMUNE RESPONSE; KIDNEY FUNCTION; NONHUMAN; PARKINSON DISEASE; PREMATURE LABOR; REVIEW; RNA STABILITY; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; XENOBIOTIC METABOLISM;

EID: 84858604500     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Fiorucci S, Meli R, Bucci M and Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase: A new avenue in anti-inflammatory therapy. Biochem. Pharmacol. (2001) 62: 1433-1438.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (1971) 231: 232-235.
3. Smith WL and Song I. The enzymology of prostaglandin endoperoxide H synthases-1 and 2. Prostaglandins and other Lipid Mediators (2002) 68-69: 115-128.
4. Hata AN and Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol. Ther. (2004) 103: 147-166.
5. Kota BP, Huang TH and Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol. Res. (2005) 51: 85-94.
6. Smith WL and Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta (1991) 1083: 1-17.
7. Griswold DE and Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med. Res. Rev. (1996) 16: 181-206.
8. Vane JR, Bakhle YS and Botting RM. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. (1998) 38: 97-120.
9. Charlier C and Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. (2003) 38: 645-659.
10. Dannhardt G and Kiefer W. Cyclooxygenase inhibitors-currunt status and future prospects. Eur. J. Med. Chem. (2001) 36: 109-126.
11. Samad TA, Sapirstein A and Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol. Med. (2002) 8: 390-396.
12. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. (1990) 265: 16737-16740.
13. Tazawa R, Xa XM, Wu KK and Wang LH. Biochemical characterization of the genomic structure, chromosomal location and promoter of human prostaglandin h synthase-2 gene. Biophys. Res. Commun. (1994) 203: 190-199.
14. Williams CS and DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am. J. Physiol. (1996) 270: G393-400.
15. Konturek PC, Kania J, Burnat G, Hahn EG and Konturek SJ. Prostaglandins as mediators of COX-2 derived carcinogenesis in gastrointestinal tract. J. Physiol. Pharmacol. (2005) 56: S57-73.
16. Yamagata K, Andreasson KA, Kaufmann WE, Barnes CA and Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron (1993) 11: 371-386.
17. Ferreri NR, An SJ and McGiff JC. Cyclooxygenase-2 expression and function in the medullary thick ascending limb. Am. J. Physiol. (1999) 277: F360-F368.
18. Kniss DA. Cyclooxygenases in reproductive medicine and biology-The role of estradiol and progesterone. J. Soc. Gynecol. Invest. (1999) 6: 285-292.
19. Garavito RM, Malkowski MG and Dewitt DL. The structures of prostaglandin endoperoxide H synthases-1 and-2. Prostaglandins and other Lipid Mediators (2002) 68-69: 129-152.
20. 2 synthase-1. Nature (1994) 367: 243-/249.
21. Kurumbail RG, Kiefer JR and Marnett LJ. Cyclooxygenase enzymes: Catalysis and inhibition. Curr. Opin. Struct. Biol. (2001) 11: 752-760.
22. Loll PJ, Picot D and Garavito RM. Nat. Struct. Biol. (1995) 2: 637-/643.
23. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC and Stallings WC. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384: 644-648.
24. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS and Simmons DL. From the cover: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc. Natl. Acad. Sci. USA (2002) 99: 13926-13931.
25. Shaftel S, Olschowka J, Hurley S, Moore A and O'Banion M. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain. Res. Mol. Brain. Res. (2003) 119: 213-215.
26. Schwab JM, Schluesener HJ, Meyermann R and Serhan CN. COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics. Prostaglandins Leukotrienes and Essential Fatty Acids (2003) 69: 339-343.
27. Simmons D. Variants of cyclooxygenase-1 and their roles in medicine. Thromb. Res. (2003) 110: 265-268.
28. Botting R. COX-1 and COX-3 inhibitors. Thromb. Res. (2003) 110: 269-272.
29. Dinchuk J, Liu R and Trzaskos J. COX-3: In the wrong frame in mind. J. Immunol. Lett. (2003) 86: 121.
30. Patrignani P, Tacconelli S, Sciulli MG and Capone ML. New insights into COX-2 biology and inhibition. Brain. Res. Rev. (2005) 48: 352-329.
31. Bertolini A, Ottani A and Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol. Res. (2001) 44: 437-/450.
32. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A and Lee CA. Prostaglandin synthase 2 gene disruptions causes severe renal pathology in the mouse. Cell (1995) 83: 473-482.
33. Chakraborty I, Das SK, Wang J and Dey SK. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J. Mol. Endocrinol. (1996) 16: 107-122.
34. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J. Rheumatol. (2001) 28: 2375-2382.
35. Gaetano G, Donati MB and Cerletti C. Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends. Pharmacol. Sci. (2003) 24: 245-252.
36. FitzGerald GA. Coxibs and cardiovascular disease. N. Engl. J. Med. (2004) 351: 1709-1711.
37. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR andPatrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothromosis? Meta-analysis of randomised trials. Br. Med. J. (2006) 332: 1302-1308.
38. Chakraborti AK, Garg SK, Kumar R, Motiwala HF and Jadhavar PS. Progress in COX-2 inhibitors: A journey so far. Curr. Med. Chem. (2010) 17: 1563-1593.
39. Reilly IA and FitzGerald GA. Inhibition of thromboxane formation in-vivo and ex-vivo: implications for therapy with platelet inhibitory drugs. Blood (1987) 69: 180-86.
40. Ritter JM, Harding I and Warren JB. Precaution, cyclooxygenase inhibition and cardiovascular risk. Trends Pharmcol. Sci. (2009) 30: 503-508.
41. Fiorucci S, Meli R, Bucci M and Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. (2001) 62: 1433-1438.
42. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O and Spano JP. Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. (2006) 59: 51-64.
43. Dannenberg AJ. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. (2001) 2: 544-551.
44. Shao J, Sheng H, Inoue H, Morrow JD and Dubois RN. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. (2000) 275: 33951-33956.
45. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA and Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression: the role of the 3′-untranslated region. J. Biol. Chem. (2000) 275: 11750-11757.
46. Subbaramaiah K and Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. (2003) 2: 96-101.
47. Eling TE, Thompson DC, Foureman GL, Curtis JF and Hughes MF. Prostaglandin H synthase and xenobitic oxidation. Annu. Rev. Pharmacol. Toxicol. (1990) 30: 1-45.
48. Wiese FW, Thompson PA and Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis (2001) 22: 5-10.
49. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. (2002) 62: 2029-2033.
50. 2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. (2002) 8: 289-293.
51. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K and DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J. Clin. Oncol. (2005) 23: 254-266.
52. Wang D, Mann JR and Dubois RN. The Role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology (2005) 128: 1445-1461.
53. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF and Gores JG. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology (2002) 35: 552-559.
54. Battu S, Rigaud M and Beneytout JL. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A. Anticancer Res. (1998) 18: 3579-3583.
55. Tuynman JB, Peppelenbosch MP and Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit. Rev. Oncol. Hematol. (2004) 52: 81-101.
56. Tsujii M, Kawano S and DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA (1997) 94: 3336-3340.
57. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC and Dubinett SM. Specific inhibition of cyclooxygenase 2 restores antitumorreactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. (2000) 164: 361-370.
58. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr. Pharm. Des. (2004) 10: 647-657.
59. McGeer PL and McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging (2007) 28: 639-647.
60. Aisen PS. Evaluation of selective COX-e inhibitors for the treatment of Alzheimer's disease. J. Pain Symp. Manage. (2002) 23: s35-40.
61. Asanuma M and Miyazaki I. Nonsteriodal anti-inflammatory drugsin experimental Parkinsonian models and Parkinson's disease. Curr. Pharm. Des. (2008) 14:1428-34.
62. Singh SK, Vobbalareddy S, Shivaramakrishna S, Krishnamaraju A, Abdul Rajjak S, Casturi SR, Akhila V and Rao YK. Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2(COX-2) inhibitors. Bioorg. Med. Chem. Lett. (2004) 14: 1683-1688.
63. Friesen RW, Dubé D, Fortin R, Frenette R, Prescott S, Cromlish W, Greig GM, Kargman S, Wong E, Chan CC, Gordon R, Xu L and Riendeau D. Novel 1,2-diarylcyclobutenes: Selective and orally active COX-2 inhibitors. Bioorg. Med. Chem. Lett. (1996) 6: 2677-2682.
64. Biava M, Porretta GC, Poce G, Supino S, Forli S, Rovini M, Cappelli A, Manetti F, Botta M, Sautebin L, Rossi A, PargolaC, Ghelardini C, Vivoli E, Makovec F, Anzellotti P, PatrignaniP and Anzini M. Cyclooxygenase-2 inhibitors: 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity. J. Med. Chem. (2007) 50: 5403-11.
65. Singh SK, Reddy PG, Rao KS, Lohray BB, Misra P, Rajjak SA, Rao YK and Venkateswarlu A. Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14: 499-504.
66. Carter JS, Kramer S, Talley JJ, Penning T, Collins P, Graneto M J, Seibert K, Koboldt CM, Masferrer J and Zweifel B. Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (1999) 9: 1171-1174.
67. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Norman BH, Rogier DJ Jr, Zweifel BS andSeibert K. 4,5-diaryloxazole inhibitors of cyclooxygenase-2 (COX-2). Med. Res. Rev. (1999) 19: 199-208.
68. Velazquez C, Rao PNP, McDonald R and Knaus EE. Synthesis and biological evaluaion of 3,4-diphenyl-1,2,5-oxadiazole-2-oxidesand 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitors/nitric oxide donor agents. Bioorg. Med. Chem. (2005) 13: 2749-2757.
69. Zarghi A, Rao PNP and Knaus EE. Synthesis and biological evaluation of methanesulfonamide analogs of rofecoxib: replacement of methanesulfonyl by methanesulfonamido decrease cyclooxygenase-2 selectivity. Bioorg. Med. Chem. (2007) 15: 1056-61.
70. Zarghi A, Rao PNP and Knaus EE. Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere. J. Pharm. Pharm. Sci. (2007) 10: 159-67.
71. Navidpour L, Shadnia H, Shafaroodi H, Amini M, Dehpour AR and Shafiee A. Design, synthesis, and biological evaluation ofsubstituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors. Bioorg. Med. Chem. (2007) 15: 1976-1982.
72. Barta TE, Stealey MA, Collins PW andWeier RM. Antiinflammatory 4,5-diarylimidazoles as selective cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett. (1998) 8: 3443-3448.
73. Joo YH, Kim JK, Kang SH, Noh MS, Ha JY, Choi JK, Lim KM, Lee CH and Chung S. 2,3-Diarylbenzopyran derivativesas a novel class of selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13: 413-17.
74. Zarghi A, Najafnia L, Daraee B, Dadrass OG and Hedayati M. Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg. Med. Chem. Lett. (2007) 17: 5634-37.
75. Zarghi A, Arefi H, Dadrass OG and Torabi S. Design and synthesis of new 2-aryl, 3-benzyl-(1,3-oxazolidine or 1,3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors. Med. Chem. Res. (2010) 19: 782-793.
76. Zarghi A, Arfaei S and Ghodsi R. Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors. Med. Chem. Res. In press.
77. Friesen RW, Brideau C, Chan CC, Charleson S, Deschenes D, Dube D, Ethier D, Fortin R, Gauthier JY, Girard Y, Gordon R, Greig GM, Riendeau D, Savoie C, Wang Z, Wong E, ViscoD, Xu LJ and Young RN. 2-Pyridinyl-3-(4-methylsulfonyl) phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (1998) 8: 2777-2782.
78. Li CS, Brideau C, Chan CC, Savoie C, Claveau D, Charleson S, Gordon R, Greig G, Gauthier JY, Lau CK, Riendeau D, Therien M, Wong E and Prasit P. Pyridazinones as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13: 597-600.
79. Orjales A, Mosquera R, Lopez B, Olivera R, Labeaga L and Nunez MT. Novel 2-(4-methylsulfonylphenyl)pyrimidine derivativesas highly potent and specific COX-2 inhibitors. Bioorg. Med. Chem. (2008) 16: 2183-2199.
80. Singh SK, Saibaba V, Ravikumar V, Rudrawar SV, DagaP, Rao CS, Akhila V, Hegde P and Rao YK. Synthesis and biologicalevaluation of 2,3-diarylpyrazines and quinoxalines as selective COX-2 inhibitors. Bioorg. Med. Chem. (2004) 12: 1881-93.
81. Caturla F, Jimenez JM, Godessart N, Amat M, Cardenas A, Soca L, Beleta J, Ryder H and Crespo MI. Synthesis and biologicalevaluation of 2-phenylpyran-4-ones: a new class of orally activecyclooxygenase-2 inhibitors. J. Med. Chem. (2004) 47: 3874-86.
82. Rao PNP, Uddin M. J and Knaus EE. Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. J. Med. Chem. (2004) 47: 3972-3990.
83. Zebardast T, Zarghi A, Daraie B, Hedayati M and Dadrass OG. Design and synthesis of 3-alkyl-2-aryl-1,3-thiazinan-4-one derivativesas selective cyclooxygenase (COX-2) inhibitors. Bioorg. Med. Chem. Lett. (2009) 19: 3162-3165.
84. Hu W, Guo Z, Chu F, Bai A, Yi X, Cheng G and Li J. Synthesisand biological evaluation of substituted 2-sulfonyl-phenyl-3-phenyl-indoles: a new series of selective COX-2 inhibitors. Bioorg. Med. Chem. (2003) 11: 1153-1160.
85. Joo YH, Kim JK, Kang SH, Noh MS, Ha JY, Choi JK, Lim KM, Lee CH and Chung S. 2,3-Diarylbenzopyran derivativesas a novel class of selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13: 413-17.
86. Khanapure SP, Augustyniak ME, Earl RA, Garvey DS, Letts LG, Martino AM, Murty MG, Schwalb DJ, ShumwayMJ, Trocha AM, Young DV, Zemtseva IS and JaneroDR. 3-[4-Methylsulfonyl)phenyl]-5-(trifluoromethyl) (2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selecselective inhibitors: synthesis and biological evaluation. J. Med. Chem. (2005) 48: 3930-3934.
87. Beswick P, Bingham S, Bountra C, Brown T, Browning K, Campbell I, Chessell I, Clayton N, Collins S, Corfield J, Guntrip S, Haslam C, Lambeth P, Lucas F, Mathews N, Murkit G, Naylor A, Pegg N, Pickup E, Player H, Price H, Stevens A, Stratton S and Wiseman J. Identification of 2,3-diarylpyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14: 5445-48.
88. Almansa C, de Arriba AF, Cavalcanti FL, Gomez LA, Miralles A, Merlos M, Garcia-Rafanell J and Forn J. Synthesis and SARof a new series of COX-2 selective inhibitors: Pyrazolo[1,5-a]pyrimidines. J. Med. Chem. (2001) 44: 350-361.
89. Baruah B, Dasu K, Vaitilingam B, Vanguri A, Casturi SR and Yeleswarapu KR. 1,2-Diaryl-1-ethanone and pyrazolo[4,3-c]quinoline-4-one asnovel selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14: 445-448.
90. Zarghi A, Zebardast T, Daraie B and Hedayati M. Design and synthesis of new 1,3-benzthiazinan-4-one derivativesas selective cyclooxygenase (COX-2) inhibitors. Bioorg. Med. Chem. (2009) 17: 5369-5373.
91. Zarghi A, Reihanfard H, Arfaei S, Daraei B and Hedayati M. Design and synthesis of new 1,2-diaryl-4,5,6,7-tetrahydro-1H-benzo[d]imidazoles as selective cyclooxygenase (COX-2) inhibitors. Med. Chem. Res. In press.
92. Zarghi A, Ghodsi R, Azizi E, Daraie B, Hedayati M and Dadrass OG. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. (2009) 17: 5312-5317.
93. Ghodsi R, Zarghi A, Daraei B and Hedayati M. Design, synthesis and biological evaluation of new 2,3-diarylquinolinederivatives as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. (2010) 18: 1029-103.
94. Zarghi A and Ghodsi R. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. (2010) 18: 5855-5860.
95. Murias M, Handler N, Erker T, Pleban K, Ecker G, SaikoP, Szekeres T and Jager W. Resveratrol analogues as selectivecyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. (2004) 12: 5571-78.
96. Uddin M. J, Rao PNP, Rahim MA, McDonald R and Knaus EE. A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selectivecyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. (2004) 14: 4911-4914.
97. Uddin MJ, Rao PNP and Knaus EE. Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2(COX-2) inhibitors. Bioorg. Med. Chem. Lett. (2004) 14: 1953-1956.
98. Uddin MJ, Rao PNP and Knaus EE. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl)alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesicactivity. Bioorg. Med. Chem. (2005) 13: 417-24.
99. Uddin MJ, Rao PNP, McDonald R and Knaus EE. Design andsynthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. Bioorg. Med. Chem. Lett. (2005) 15: 439-442.
100. Chen QH, Rao PNP and Knaus EE. Design, synthesis, and biologicalevaluation of linear 1-(4-,3-or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase inhiobitors. Bioorg. Med. Chem. (2005) 13: 6425-6434.
101. Tsai WJ, Shiao YJ, Lin SJ, Chiou WF, Lin LC, YangTH, Teng CM, Wu TS and Yang LM. Selective COX-2 inhibitors. Part 1; synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg. Med. Chem. Lett. (2006) 16: 4440-4443.
102. Lin SJ, TsaiWJ, Chiou WF, Yang TH and Yang LM. Selective COX-2 inhibitors. Part 2; synthesis and biological evaluationof 4-benzylideneamino-and 4-phenyliminomethylbenzenesulfonamides. Bioorg. Med. Chem. (2008) 16: 2697-706.
103. Zarghi A, Arfaee S, Rao PNP and Knaus EE. Design, synthesis and biological evaluation of 1,3-diarylprop-2-en-1-ones: a novelclass of cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. (2006) 14: 2600-2605.
104. Zarghi A, Zebardast T, Hakiminon F, Shirazi FH, Rao PNP and Knaus EE. Synthesis and biological evaluation of 1,3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors. Bioorg. Med. Chem. (2006) 14: 7044-50.
105. Arfaie S and Zarghi A. Design, synthesis and biological evaluation of new (E)-and(Z)-1,2,3-triaryl-2-propen-1-ones as selective COX-2 inhibitors. Eur. J. Med. Chem. (2010) 45: 4013-4017.
106. Zarghi A, Kakhgi S, Hadipoor A, Daraee B, Dadrass OG and Hedayati M. Design and synthesis of 1,3-diarylurea derivatives asselective cyclooxygenase (COX-2) inhibitors. Bioorg. Med. Chem. Lett. (2008) 18: 1336-1339.
107. Barnett JW, Dunn JP, Kertesz DJ, Morgans AB, Ramesha CS, Sigal CE, Sjogren EB, Smith DB and Talamas DB. Title??? Eur. Pat. Appl. EP 714895; Chem. Abstr. 125, 142546.
108. Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, KoehlerJ, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S and MarshallPJ. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol. (2005) 144: 538.
109. Kalgutkar AS, Crews BC, Saleh S, Prudhomme D and Marnett LJ. Indolyl esters and amides related to indomethacin areselective COX-2 inhibitors. Bioorg. Med. Chem. (2005) 13: 6810-6822.